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Abstract Primary percutaneous coronary intervention is the
best treatment of patients with ST elevation myocardial infarc-
tion (STEMI).Whenmanaging a STEMI patient, our approach
must be rapid and aggresive in order to interrupt the patholog-
ical process of thrombus formation and stabilization. The
therapy must be initiated prior to angiography (pretreatment),
continued during the procedure (periprocedural), recovery
phase (in-hospital), and follow-up. The treatment strategies
resulting in thrombus dissolution/extraction have focused on
optimization of both pharmacological and interventional ther-
apies. At present, there is no optimal evidence-based approach
to all patients with STEMI, and the treatment of these
patients needs to be modified with respect to the risk
profile, availability of medical resources, and our experi-
ence. In this review, we summarize current pharmacological
and interventional strategies used in the setting of STEMI
and discuss potential benefits of novel dosing regimens and
combinations of drugs and techniques.
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Introduction
During the course of acute myocardial infarction with ST
elevations (STEMI), where symptoms prevail and/or the
time delay from the onset of chest pain to the first medical
contact is <12 h, the opening of culprit coronary artery must
be our major concern. One can achieve this by performing
primary percutaneous coronary intervention (PCI) as early
as possible or by applying fibrinolytic therapy where PCI is
not available and/or the expected time delay to PCI is longer
than 120 min (our goal is to achieve the time-to-treatment
delay from first medical contact (FMC) to wire passage
≤90 min and in high-risk patients with large anterior infarcts
and early presenters within 2 h≤60 min). If reperfusion
therapy is fibrinolysis, the goal is to reduce this delay
(FMC to needle) to ≤30 min [1]. Both strategies involve
the use of an anticoagulant (heparin [2] or preferably enox-
aparine [3, 4]) and aspirin. The outcome of patients may be
improved both with the use of adjunctive antithrombotic
medication—glycoprotein (GP) IIb/IIIa inhibitors, adeno-
sine diphosphate (ADP) receptor blockers, direct thrombin
inhibitors—or mechanical removal of occluding thrombotic
mass. To optimize the therapy of STEMI patients, with the
support of clinical trials results and our best clinical judgement
and experience, we can successfully reduce both bleeding and
thrombotic adverse events and improve immediate outcome
(thrombolysis in myocardial infarction (TIMI) arterial flow,
myocardial blush grade (MBG), ST segment resolution
(STR)), short-, and long-term survival when combining
pharmacological and mechanical approaches. In this review,
we will summarize indications of antithombotic drugs and




Ticlopidine was the first P2Y12 ADP- receptor blocker used in
combination with aspirin to reduce thrombotic events com-
pared with warfarin after stent implantation [5]. It had never
been tested in the setting of STEMI. Due to its side-effects
(neutropenia, rash, gastrointestinal intolerance), ticlopidine
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was gradually replaced by the ten times more potent and safer
antiplatelet agent clopidogrel.
In the era of fibrinolytic therapy of STEMI, clopidogrel
when added to aspirin reduced the combined cardiovascular
endpoint by 9 % and death by 7 % in the COMMIT (ClO-
pidogrel and Metoprolol in Myocardial Infarction Trial) trial
[6]. When a loading dose of 300 mg and subsequent main-
tenance dose of 75 mg daily were administered prior to
fibrinolysis, the 20 % relative risk reduction was observed
within a 30-day follow-up in STEMI patients in the CLAR-
ITY (Clopidogrel as Adjunctive Reperfusion Therapy) trial
[7]. In concordance with other clopidogrel trials, dual anti-
platelet therapy is indicated in STEMI patients for 12 months.
An observational study of 255 consecutive STEMI patients
showed a significantly lower incidence of post-PCI myocar-
dial blush grade 0 or 1 (odds ratio, 0.64; 95 % confidence
interval 0.43 to 0.96, p=0.03) and significantly less common
no-reflow phenomenon (odds ratio, 0.38; 95 % confidence
interval 0.15 to 0.98, p=0.04) when a 600-mg loading dose
had been applied compared with a 300-mg loading dose
group. Also, higher 1-year survival free of major adverse
cardiac events was observed in the 600-mg group (hazard
ratio, 0.57; 95 % confidence interval 0.33 to 0.98, p=0.04)
[8]. A relatively small but randomized study in 201 STEMI
patients found results supporting the use of the 600-mg load-
ing dose in the setting of STEMI (lower median creatine
kinase-myocardial band, troponin I, less TIMI flow<3 after
PCI, better left ventricular ejection fraction, and fewer 30-day
major adverse cardiovascular events) [9]. The 600-mg loading
dose has been adopted worldwide. Moreover, the 600-mg
loading dose followed by a 150-mg maintenance dose for
7 days further improves short-term outcome in STEMI
patients treated with primary PCI [10]. These clinical findings
might be associated with more pronounced decrease of resid-
ual platelet activity achieved with more aggressive loading
dose that helps overcome clopidogrel resistance [11]. Accord-
ing to the results of several genetic substudies, there are two
major determinants of clopidogrel resistance—polymorphism
of P-glycoprotein (ACBC1, absorption) and cytochrome P450
isoenzyme CYP2C19 (two-step metabolic activation). Up to
20–40 % of patients are either non-responders or poor res-
ponders to clopidogrel therapy [12], resulting in potential
negative clinical consequencies.
Prasugrel was the first out of two novel potent antiplatelet
drugs to appear on the market. It also blocks thrombocytes
irreversibly but requires just a single-step metabolic oxydation
that is CYP2C19-independent, and as such, the activation of
the prodrug is more rapid, efficient, and genetically much less
determined when compared with clopidogrel [13]. In
clopidogrel-naive STEMI patients in the TRITON (TRial to
Assess Improvement in Therapeutic Outcomes by Optimizing
Platelet InhibitioN with Prasugrel) TIMI 38 trial, prasugrel
given prior to primary PCI significantly reduced the composite
cardiovascular endpoint both at 30 days (hazard ratio (HR)=
0.68) and 15 months (HR=0.79) when compared with clopi-
dogrel. The incidence of myocardial infarction and particularly
stent thrombosis at 15 months was also lower with prasugrel
(HR=0.75 and HR=0.58, respectively). Unlike other sub-
groups, the STEMI patients profited from prasugrel therapy
with no increase of major and life-threatening bleeding. The
concomitant use of GP IIb/IIIa inhibitors further improved
patients’ outcome. In patients without prior stroke, aspirin+
fractionated/unfractionated heparin+prasugrel with/without
GP IIb/IIIa blocker is an evidence-based approach in the
setting of STEMI [14].
Ticagrelor is a reversible ADP receptor blocker with no
metabolic activation required. It is even more efficient in
reducing residual platelet activity in acute coronary syndrom
(ACS) patients than prasugrel [15]. When administered on
top of clopidogrel or to clopidogrel-naive patients in the
setting of STEMI, ticagrelor significantly reduced the inci-
dence of myocardial infarction (HR=0.80), stent thrombosis
(HR=0.66), and all-cause mortality (HR=0.87) at 12 months
when compared with clopidogrel in the PLATO (PLATelet
inhibition and patient Outcomes) trial [16]. There was no
substantial increase of major and life-threatening bleeding
but notably higher incidence of stroke (HR=1.63). Reduc-
tion of the primary composite efficacy endpoint was not
observed. The concomitant use of GP IIb/IIIa inhibitors
did not further improve patients’ outcome.
To sum up, both prasugrel and ticagrelor are as safe as
clopidogrel but more efficient in the setting of STEMI. The
indirect comparison available prefers prasugrel over ticagre-
lor in patients presenting with STEMI.
Prasugrel or ticagrelor or clopidogrel should be adminis-
tered as soon as the diagnosis has been made in most of
STEMI patients prior to angiography. Respecting the fact
that prasugrel pretreatment is associated with a markedly
increased risk of coronary artery bypass graft-related major
bleeding, both in overall ACS population and STEMI sub-
group (HR=8.19), in patients where the diagnosis is doubt-
ful (Fig. 7 on the right) or their risk profile predisposes to
bleeding complications, we suggest preloading with clopi-
dogrel or ticagrelor. In centers preferring prasugrel applica-
tion, this should be held until angiografic findings have
confirmed an acute thrombotic occlusion.
Glycoprotein IIb/IIIa Inhibitors (GPI)
Platelet GP IIb/IIIa receptor blockers (abciximab, tirofiban,
eptifibatide) inhibit final common pathway of aggregation
process by preventing fibrinogen from binding to activated
thrombocytes and forming white thrombus. Depending on an
agent used, the platelet inhibition achieved is selective, com-
petitive, and short-lasting (up to 4 h) for small molecules
(tirofiban, eptifibatide) and non-competitive, long-lasting (up
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to 72 h), and with affinity to several other receptors of which
the inhibition might be also beneficial (abciximab) [17]. More-
over, all these agents have been found to improve microcircu-
larory function, reduce platelet-released vasoactive molecules,
and improve short- and long-term outcomes, particularly in
early comers (<4 h) and diabetic patients.
Several randomized trials evaluated GPIs in the setting of
STEMI. The most profound evidence has been found for
abciximab in combination with heparin [18, 19]. A 30 %
odd reduction in the composite ischemic endpoint was
demontrated with the adjunctive use of abciximab [18].
Recently, eptifibatide was compared with abciximab in the
primary PCI setting, and non-inferiority was found [20].
Tirofiban was shown to improve the composite ischemic
endpoint versus placebo but seemed to perform worse than
abciximab. As a consequence, abciximab remains the drug
of choice [21]. Due to the increased risk of bleeding when
recommended dosing of GPIs is co-administered, the com-
bination therapy is indicated in high-risk clinical situations
as bailout therapy (large thrombus, no-flow phenomenon
after PCI).
In clinical trials, abciximab is usually administered as an
intravenous bolus +12-h continuous infusion on top of hep-
arin/bivalirudin. The dosing of the other drugs—eptifibatide
and tirofiban—consists of one and two, respectively,
weight-balanced boluses and an 18-h maintenance infusion.
Recently, there have been published studies testing a poten-
tial benefit of intracoronary bolus of GPIIb/IIIa inhibitors in
order to increase intracoronary concentration of the
drug, resulting in more pronounced local effect on
thrombus dissolution. Meta-analysis by Friedland et al.
[22] demonstrated favorable effect of intracoronary bo-
lus on TIMI flow, target vessel revascularization, and
short-term mortality after PCI with no increase of bleed-
ing complications. With a rationale that more potent
ADP receptor blockers, bivalirudin, thrombus aspiration,
and primary stenting are available for most of the
STEMI patients and that the continuous intravenous
infusion might not be benefitial to further improve out-
come but increase the risk of bleeding, Gu et al. [23]
applied intracoronary bolus of abciximab only with no
maintenance infusion and found better blush grade and
reduced infact size in those with intracoronary applica-
tion of abciximab. The intracoronary application of
abciximab results in lower platelet reactivity in coronary
sinus blood samples when compared with intravenous
dosing [24]. A randomized trial comparing these regi-
mens with/without maintenance infusion in combination
with modern mechanical reperfusion devices needs to be
performed. Until then, the use of intracoronary bolus
with/without subsequent infusion is questionable but
supported by several studies and also by our clinical
experience.
Bivalirudin
The direct thrombin inhibitor bivalirudin has been studied in
various clinical settings. Many studies and meta-analyses
demonstrated similar efficacy in reduction of ischemic
events but much lower risk of major bleeding (45 % reduc-
tion) when compared with heparin with/without adjunctive
GPI [25]. The reduction of bleeding events, no association
with thrombocytopenia, no need for any co-factor for activ-
ity, and no potential to activate platelets (when compared
with heparin+abciximab) might have been responsible for
an overall mortality benefit in several trials. All these studies
used transfemoral access site where bleeding complications
are more frequent than when performing via radial artery.
Secondly, comparisons of heparin+GPI versus bivalirudin
and pure unfractionated heparin versus bivalirudin provide
conflicting results. It seems that bivalirudin is as safe as
heparin concerning major bleeding events with a trend to
more frequent stent thrombosis and cardiovascular ischemic
events. On the other hand, when abciximab is administered
on top of heparin, this combination causes more major
bleeding that drives the net clinical benefit toward bivalir-
udin [17]. This serves as a rationale for a bail-out therapy
with GPIs in high-risk patients. Where the risk of bleeding is
an issue, intracoronary bolus of GPI and no infusion strategy
may be useful.
A recent study by Stone et al. demontrated a reduction of
infarct size after intracoronary bolus of abciximab on top of
bivalirudin anticoagulation in patients with anterior STEMI
treated with drug-eluting stent implantation with/without
prior thrombus aspiration [26].
Both in the TRITON and the PLATO trial, combinations
of the investigational product with bivalirudin were used in
just a few cases, and no subanalyses have been published
describing potential benefits of prasugrel or ticagrelor on top
of bivalirudin therapy. Despite this fact, with respect to
clinical relevance of bivalirudin as an anticoagulant in the
setting of STEMI, there is no logical reason not to apply
prasugrel or ticagrelor to our patients who have had/are
intended to have anticoagulation therapy with bivalirudin.
We believe that the choice of an appropriate combination
of drugs needs to be individualized with respect to patient’s
risk profile (bleeding versus prothrombotic), coronary pa-
thology (prognostic significance, complex leasion), selected
interventional strategy (thrombus aspiration), and our good
clinical judgement.
Mechanical Reperfusion for STEMI
As mentioned previously, the primary PCI is the preferred
reperfusion strategy in all patients with STEMI, if the time-
to-treatment delay is less than 90–120 min (Figs. 1 and 2).
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Currently, there is a large variation of reperfusion techniques
available, from more historical and simple ballooning to
rather complex reperfusion strategies.
Coronary Stents
Bare-Metal Stents (BMS)
Routine bare-metal stent implantation was associated with
higher benefit compared with simple balloon dilation in
several trials [27, 28]. Since then, based on higher effective-
ness and decrease of the peri- and postprocedural risk after
stenting, this strategy has been applied in majority of the
STEMI patients. If feasible, the direct stenting without pre-
dilation should be preferred [29].
Drug-Eluting Stents (DES)
The drug-eluting stent (DES) era started in 2002 in elective
procedures with very promising results. The first-generation
DES implantation in STEMI was safe and reduced the risk
of repeat target vessel revascularization [30]. The potential
higher risk of late and very late stent thrombosis raised at the
ESC congress in 2006 was not clinically proved [30]. The
second-generation DES was shown to be even safer than
modern BMS in consecutive STEMI patients without losing
the benefits [31]. Patients’ compliance with the need of
longer dual antiplatelet therapy has become less important
with the latest types of DES. This may be the strongest
argument for the DES to “win the BMS versus DES bat-
tle”—at least, until the time when fully resorbable DES for
STEMI would be present.
Dedicated Stents
Managing acute clinical situations and unstable thrombotic
leasions (Fig. 3) raise the need for specially designed or
dedicated stents. Achievement of a really optimal result after
the stent implantation on the epicardial (Fig. 4) as well as on
the myocardial level is crucial for the short- and long-term
patients’ outcome.
Often seen spastic reaction of the infarct-related artery
(IRA) and the presence of thrombus may be the reason for
implanting the stents with progessive self-apposing after its
implantation. The interim analysis of 600 patients in the
APPOSITION III trial using the self-expanding BMS showed
promising secondary endpoint results with 3.5 % rate of major
cardiovascular advers events (MACE) including death, repeat
target-vessel myocardial infarction, emergent bypass surgery,
or clinically driven target vessel revascularisation at 30 days.
Fig. 1 Anterior STEMI with acute thrombotic occlusion of the left
anterior descending artery (LAD), prior intervention
Fig. 2 Anterior STEMI with acute thrombotic occlusion of the left
anterior descending artery (LAD, as on Fig. 1), treated by thromboas-
piration and DES implantation, final result
Fig. 3 Optical coherent tomography (OCT) image of acute thrombotic
occlusion of LAD, showing large thrombotic mass
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The MACE at 12 months as the primary endpoint of the study
should be available in 2013.
Managing thrombi and preventing distal embolizations
is another target in STEMI where a special mesh-covered
stent type can be helpful. This concept showed promising
surrogate data in the multicenter single-arm MAGICAL
trial (MGuard in Acute MI TriaL) in 60 patients [32],
further confirmed in the randomized MASTER trial
(MGuard for Acute ST Elevation Reperfusion) using the
novel type of stent in 432 patients [33]. Complete ST
segment resolution (STR>70 %) at 60 and 90 min togeth-
er with restoring normal blood flow (TIMI-3 flow) was
significantly better than after implantation of standard
types of stents (57.8 % versus 44.7 %, P=0.008 and 91.7 %
versus 82.9%, P=0.006). On the contrary, no difference in the
myocardial blush grade was present (MBG 2/3 83.9 % versus
84.7 %, P=0.81).
Thrombectomy
One of the challenging situations in interventional car-
diology is the thrombus management, especially in the
presence of large thrombus burden. Such situation is
associated with an increased risk of distal embolization,
no-reflow phenomenon, and worse clinical outcome in-
cluding late mortality [34]. The role of thrombectomy
during primary PCI has been tested for many years, and
recently, its role has been established based on the data
from randomized trials and meta-analyses. On the other
hand, and especially in the era of new pharmacological
regimens, it is important to know whether to use the
thrombectomy in all patients or selectively and whether
this adjunctive technique would have a clear impact on
mortality reduction.
Manual Thrombectomy
The current Class IIa indication for manual aspiration throm-
bectomy during primary PCI in ESC [1] and ACC/AHA [35]
Guidelines is based on two major randomized trials and sev-
eral meta-analyses.
The TAPAS (Thrombus Aspiration during Percutaneous
coronary intervention in Acute myocardial infarction Study)
was the first one showing the clinical benefit of manual
thrombectomy using the Export catheter (Medtronic Inc.,
Minneapolis, MN) versus primary PCI alone in 1,071
patients, though as the secondary and not pre-specified
endpoint (mortality at 1 year 3.6 % versus 6.7 %, p=
0.018) [36, 37]. In 72 % of patients, some visible material
was retracted from the IRA, and the aspiration was possible
in 90 % of cases. Primary surrogate endpoint comprised the
achievement of optimal reperfusion on myocardial level
(MBG-3 in 46 % versus 32 %, p<0.001). Thromboaspira-
tion was associated also with higher complete STR rate
(57 % versus 44 %, p<0.001). There are two concerns about
the study: single-center experience and “classical” routine
balloon predilation before stenting.
Further on, using a similar design and type of aspiration
catheter, the EXPIRA (thrombectomy with EXPort catheter
in Infarct Related Artery during primary percutaneous cor-
onary intervention) trial showed a significant improvement
in the primary endpoints of MBG≥2 and complete STR in
175 patients (88 % versus 60 %, p=0.001; and 64 % versus
39 %, p=0.001) [38]. In a 75-patient substudy with contrast-
enhanced magnetic resonance imaging, the use of aspiration
was found to be effective in decreasing the infarct size both
in the acute phase and at 3 months (1.7 g versus 3.7 g, p=
0.0003 and 17 % versus 11 %, p=0.004). Cardiac death was
less frequent in the thromboaspiration arm at 9 months (0 %
versus 4.6 %, p=0.02).
The real clinical potential of manual aspiration technique
is expected to come from the large TASTE ( Thrombus
Aspiration in ST-Elevation Myocardial Infarction in Scandi-
navia) trial with more than 5,000 patients and the TOTAL
(Randomized Trial of Routine Aspiration ThrOmbecTomy
with Percutaneous Coronary Intervention (PCI) versus PCI
ALone in Patients with STEMI Undergoing Primary PCI)
trial enrolling 4,000 patients.
Mechanical Thrombectomy
Currently, there are several devices available for mechanical
thrombectomy during primary PCI (e.g., AngioJet, X-Sizer,
and Rescue), but mostly conflicting results of the trials do
not support its routine use during primary PCI [1].
The use of AngioJet Rheolytic Thrombectomy (Medrad
Interventional/Possis, Minneapolis, MN) was studied in two
relatively large randomized trials. In both the AIMI (AngioJet
Fig. 4 OCT image of LAD (as on Fig. 3) after thromboaspiration and
subsequent DES implantation with optimal stent apposition
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Rheolytic Thrombectomy in Patients Undergoing Primary An-
gioplasty for Acute Myocardial Infarction) [39] and JET-
STENT (AngioJet Rheolytic Thrombectomy Before Direct
Infarct Artery Stenting in Patients Undergoing Primary PCI
for Acute Myocardial Infarction) [40] trials, the primary end-
points were not met. In 480 patients in the AIMI trial, the use of
rheolytic thrombectomy (RT) was associated with the increase
of infarct size (p=0.03), reduction in TIMI-3 flow (p<0.05),
and higher MACE rate at 30 days (p=0.01). In the JESTENT
trial, the use of RT was compared with direct stenting group.
Although 501 patients were selected based on the angiographic
evidence of larger thrombus grades 3 to 5, co-primary end-
points (STR and infarct size) showed no difference between the
two treatment strategies. It is difficult to understand the lower
rate of MACE in the RT group at 6 and 12 months because of
the similar infarct size (11.8 % versus 12.75 %, p=0.40) and
only higher STR rate (85.8 % versus 78.8 %, p=0.043).
The X-Sizer device (eV3,White Bear Lake, MN, USA) was
used in the XAMINE ST (X-Sizer for Thrombectomy in Acute
Myocardial Infarction Improves ST-Segment Resolution:
Results of the X-Sizer in AMI for Negligible Embolization
andOptimal ST Resolution) Trial in 201 patients with occluded
IRA [41]. Primary end point (partial STR>50 %) was found to
be more frequent in the mechanical device group (p=0.037),
but, together with lower distal embolization rate, these surro-
gate benefits did not result in any clinical improvement.
Manual Versus Mechanical Thrombectomy
Presently, such comparison is clinically much more relevant
but with very limited data. In the TREAT-MI (A Randomized
comparison of manual versus mechanical thrombus removal in
primary percutaneous coronary intervention in the treatment of
ST-segment elevation myocardial infarction) Trial, the X-Sizer
was compared with the Export aspiration catheter [42]. Proce-
dural parameters as well as the occurrence of primary clinical
endpoint in 201 patients at 3 years were similar except for the
more often successfully deployed Export catheter with a trend
toward better ST-segment resolution (56.6 % versus 44 %; p=
0.06) as compared with the X-sizer system. Burzotta et al.
performed a meta-analysis of 2,686 patients in 11 randomized
trials (from the total of 17 eligible) with manual (1,815 patients
with the use of Diver CE, Pronto and Export catheters) and
mechanical thrombectomy (871 patients with the use of X-
Sizer, Angiojet, Rescue and TVAC devices) on an individual
basis [43]. At 1 year, the clinical benefit of thrombectomy was
clearly defined (p=0.049 for all-cause mortality; p=0.011 for
MACE). Subgroups analysis showed better survival rate after
thrombectomy also in patients treated with glycoprotein
IIb/IIIa inhibitors (p=0.045), and this benefit was confined to
the manual aspiration. Selection of the trials was dependent on
the authors’ agreement with providing the data.
On the contrary, the Bayesian meta-analysis of 21 ran-
domized trials with manual (16 trials) and mechanical
thrombectomy (4,299 patients) performed by Mongeon et
al. did not show any clinical impact of thrombectomy, but
there was a consistent improvement in surrogate endpoints
(complete STR, final TIMI3 flow, and less no-reflow) [44].
Manual aspiration thrombectomy is currently the pre-
ferred method of thrombus extraction that is fast, broadly
applicable, relatively effective, and user-friendly. The more
complex mechanical extraction techniques might be useful
or even required to completely manage the large thrombus
burden. Nevertheless, the role of thrombectomy is less
established in scenarios where the IRA is patent with initial
or post-wiring TIMI 2–3 flow without angiographic evi-
dence of larger thrombus. Direct stenting seems to be the
best approach to such patients (Fig. 5).
Pharmacologic Reperfusion for STEMI=Fibrinolysis
In patients not able to be treated with primary PCI within the
recommended time-interval, there is an important role of
a) b)Fig. 5 Inferior STEMI withthrombotic leasions in proximal
right coronary artery (RCA),
initial TIMI II flow: a large
thrombotic mass managed by
thromboaspiration afterward; b
little thrombotic mass managed
by direct stenting afterward
J. of Cardiovasc. Trans. Res. (2013) 6:378–387 383
Fig. 6 Simplified algorithm of
STEMI treatment based on the
current European practice
guidelines [1]. STEMI acute




stent; BMS bare-metal stent;UFH
unfractionated heparin; GP IIb/
IIIa glycoprotein receptor IIb/IIIa;
CA coronary angiography; s.c.
subcutaneous. Classes of
recommendations: I = is
recommended/is indicated, IIa =
should be considered, IIb = may
be considered; Level of evidence:
A = data derived from multiple
randomized clinical trials or meta-
analyses, B = data derived from a
single randomized clinical trial or
large non-randomized studies,
C = consensus of opinion of the
experts and/or small studies,
retrospective studies, registries
Fig. 7 Current local algorithm of the STEMI treatment in high-volume
primary PCI center. STEMI acute myocardial infarction with ST-elevation;
ECG electrocardiogram; EMS emergency medical service; TIA transient
ischemic attack; UFH unfractionated heparin; PCI percutaneous coronary
intervention; TIMI thrombolysis in myocardial infarction; GP IIb/IIIa
glycoprotein receptor IIb/IIIa; LAD left anterior descending coronary
artery; DES drug-eluting stent; BMS bare-metal stent; CABG coronary
artery bypass graft; ECHO echocardiography; CA coronary angiography
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fibrinolysis. The general limitations of fibrinolysis were
well described at the beginning of the European Stent for
Life Initiative in 2010 [45]. In 30 European countries, the
“reperfusion paradox” was well demonstrated. In contrast to
the “primary PCI countries,”,a high rate of non-reperfused
STEMI patients was observed in countries with the “simple
and deliverable” fibrinolysis as the preferred reperfusion
treatment strategy.
There are several different fibrinolytic drugs available—
from the fibrin-non-specific, least effective, but broadly avail-
able streptokinase for intravenous (i.v.) infusion to the more
potent and fibrin-specific tissue plasminogen activator (tPA;
alteplase–i.v. bolus+infusion), reteplase (rPA–double i.v. bo-
lus), or tenecteplase (TNK-tPA–single i.v. bolus). The major
hazard of fibrinolysis is the excess risk of bleeding including
the cerebral hemorhage. Moreover, with increasing time-delay,
particularly after 6 h, the overall efficacy of thrombolysis
decreases. Albeit the fibrinolytic facilitation of primary PCI
is not indicated, the routine transportation to coronary angiog-
raphy or PCI after its administration (respecting several contra-
indications) is routinely recommended.
It is important to realize that, because of several factors,
in real life, there may be differences between the step-by-
step algorithm recommended by current highly sophisticat-
ed guidelines (Fig. 6) and adjusted algorithms followed in
the daily practice. We provide an example of the STEMI
algorithm being used in our high-volume primary PCI cen-
ter situated in one of the European “best STEMI practice
countries” (Fig. 7).
Unanswered Questions
Despite the precise current data, some questions still remain
unanswered: (1) the timing and method of the potent antipla-
telet therapy application (pre- and in-hospital), (2) the type and
method of anticoagulation agent application (LMWH, UFH,
bivalirudin), (3) the optimal primary PCI technique including
the thrombus-removing devices, and (4) the role of imaging.
Respecting the recommended practice guidelines, there is
a continuous need for individual approach especially to
high-risk patients with both tendency to bleeding, thrombot-
ic, and ischemic events.
Conclusion
The pharmaco-mechanic approach to patients presenting with
STEMI is very complex including novel potent antiplatelet
drugs, new regimens of therapy, and new promising interven-
tional techniques. There is a lot of data regarding pharmaco-
logic and interventional treatments, but there is a lack of data
showing their potential when used in mutual combination.
The evidence-based approach needs to be modified to each
clinical situation based on the best clinical judgment.
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